Most major insurers now offer member-facing cost estimator tools, and a growing number of independent platforms aggregate price transparency data to help patients compare costs across providers before scheduling a non-emergency procedure. The core question these tools raise is whether patients actually use them, and whether doing so meaningfully reduces spending — a question health services researchers have studied with results more mixed than the tools' marketing suggests.
Utilization Rates Remain Persistently Low
Multiple studies tracking actual usage of insurer-provided cost estimator tools have found utilization rates in the low single digits of eligible members, even when a tool is genuinely available and reasonably well-designed — a persistent gap between tool availability and actual patient engagement that has puzzled health policy researchers given the theoretical financial incentive patients in high-deductible plans, in particular, would seem to have to use them.
Several Structural Factors Explain the Low Usage
Research examining this gap has identified several contributing factors: many patients are unaware the tool exists at all, healthcare decisions are frequently made under time pressure or physician referral momentum that does not naturally pause for price comparison, and for many services, patients defer heavily to their physician's specific referral recommendation regardless of relative cost, treating the referral as a trust-based clinical decision rather than a price-comparable commodity purchase.
Where Cost Estimator Tools Have Shown Genuine Savings
Despite low overall utilization, studies of patients who do use cost estimator tools for genuinely shoppable, elective, non-urgent procedures — imaging studies like MRIs, certain elective surgeries, and lab testing — have found meaningful reductions in the price paid compared to non-users, suggesting the tools do work as intended for the specific subset of patients who engage with them and for services where meaningful choice actually exists. This finding has reinforced that the barrier is primarily usage and awareness rather than the tools' fundamental value once used.
Elective, Shoppable Services Are a Small Share of Total Spending
A structural limitation researchers consistently note is that genuinely shoppable services — where a patient has time to compare prices and a meaningful choice of provider — represent a relatively modest share of total healthcare spending. Emergency care, inpatient hospitalization, and complex chronic disease management, which together account for a much larger share of total spending, offer far less realistic opportunity for price comparison shopping given clinical urgency or the complexity of coordinating care with an established treatment team.
Employer-Driven Incentive Programs Have Shown Stronger Engagement
Some employers have layered direct financial incentives on top of cost estimator tool availability — sharing a portion of the savings directly with an employee who selects a lower-cost, quality-verified provider for a shoppable service — and these incentive-based programs have generally shown meaningfully higher engagement rates than tool availability alone, suggesting that a direct financial nudge, not just information availability, may be necessary to meaningfully shift patient shopping behavior at scale.
Conclusion
Healthcare cost estimator tools deliver genuine savings for the patients who actually use them on shoppable services, but persistently low awareness and utilization, combined with the reality that most healthcare spending occurs in less shoppable clinical contexts, have limited their broader impact on total healthcare spending so far. Facilities supporting elective, price-comparable service lines rely on efficient diagnostic equipment to deliver competitively priced imaging and testing services.
